Retinoic acid receptor-α up-regulates proopiomelanocortin gene expression in AtT20 corticotroph cells

Endocrine Journal

Volumn 61, Issue 11, 2014, Pages 1105-1114

  Uruno, Akira ^a   Saito Hakoda, Akiko ^a   Yokoyama, Atsushi ^a   Kogure, Naotaka ^a   Matsuda, Ken ^a   Parvin, Rehana ^a   Shimizu, Kyoko ^a   Sato, Ikuko ^a   Kudo, Masataka ^a   Yoshikawa, Takeo ^a   Kagechika, Hiroyuki ^b   Iwasaki, Yasumasa ^c   Ito, Sadayoshi ^a   Sugawara, Akira ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c KOCHI UNIVERSITY   (Japan)

Author keywords

ACTH; Pomc; RAR

Indexed keywords

CORTICOTROPIN; NEUROGENIC DIFFERENTIATION FACTOR; PROOPIOMELANOCORTIN; RETINOIC ACID RECEPTOR ALPHA; TPIT PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; BENZOIC ACID DERIVATIVE; RETINOIC ACID RECEPTOR; TAMIBAROTENE; TETRALIN DERIVATIVE;

ACTH SECRETING CELL; ARTICLE; CONTROLLED STUDY; CORTICOTROPIN RELEASE; GENE ACTIVITY; GENE EXPRESSION REGULATION; GENE INTERACTION; GENE MUTATION; GENE OVEREXPRESSION; GENE REPRESSION; GENE SILENCING; MUTATIONAL ANALYSIS; PROMOTER REGION; PROOPIOMELANOCORTIN GENE; PROTEIN PROTEIN INTERACTION; TRANSACTIVATION; AGONISTS; ANIMAL; BIOSYNTHESIS; MOUSE; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; BENZOATES; CELL LINE, TUMOR; MICE; PRO-OPIOMELANOCORTIN; RECEPTORS, RETINOIC ACID; TETRAHYDRONAPHTHALENES;

EID: 84912135381     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ14-0115     Document Type: Article

References (37)

1. Uruno A, Sugawara A, Kudo M, Sato M, Sato K, et al. (2003) Transcription suppression of thromboxane receptor gene expression by retinoids in vascular smooth muscle cells. Hypertens Res 26: 815-821.
2. Uruno A, Sugawara A, Kanatsuka H, Kagechika H, Saito A, et al. (2005) Upregulation of nitric oxide production in vascular endothelial cells by all-trans retinoic acid through the phosphoinositide 3-kinase/Akt pathway. Circulation 112: 727-736.
3. Saito A, Sugawara A, Uruno A, Kudo M, Kagechika H, et al. (2007) All-trans retinoic acid induces in vitro angiogenesis via retinoic acid receptor: possible involvement of paracrine effects of endogenous vascular endothelial growth factor signaling. Endocrinology 148: 1412-1423.
4. Uruno A, Noguchi N, Matsuda K, Nata K, Yoshikawa T, et al. (2011) All-trans retinoic acid and a novel synthetic retinoid tamibarotene (Am80) differentially regulate CD38 expression in human leukemia HL-60 cells: possible involvement of protein kinase C-δ. J Leukoc Biol 90: 235-247.
5. Flynn PJ, Miller WJ, Weisdorf DJ, Arthur DC, Brunning R, et al. (1983) Retinoic acid treatment of acute promyelocytic leukemia: in vitro and in vivo observations. Blood 62: 1211-1217.
6. Lotan R (1996) Retinoids and their receptors in modulation of differentiation, development, and prevention of head and neck cancers. Anticancer Res 16: 2415-2419.
7. Páez Pereda M, Missale C, Grübler Y, Arzt E, Schaaf L, et al. (2000) Nerve growth factor and retinoic acid inhibit proliferation and invasion in thyroid tumor cells. Mol Cell Endocrinol 167: 99-106.
8. Soprano KJ, Purev E, Vuocolo S, Soprano DR (2006) Rb2/p130 and protein phosphatase 2A: key mediators of ovarian carcinoma cell growth suppression by all-trans retinoic acid. Oncogene 25: 5315-5325.
9. Pasquali D, Rossi V, Bellastella G, Bellastella A, Sinisi AA (2006) Natural and synthetic retinoids in prostate cancer. Curr Pharm Des 12: 1923-1929.
10. Schteingart DE (2009) Drugs in the medical treatment of Cushing’s syndrome. Expert Opin Emerg Drugs 14: 661-671.
11. Fleseriu M, Petersenn S (2012) Medical management of Cushing’s disease: what is the future? Pituitary 15: 330-341.
12. Nieman LK (2002) Medical therapy of Cushing’s disease. Pituitary 5: 77-82.
13. Heaney AP, Fernando M, Yong WH, Melmed S (2002) Functional PPAR-γ receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med 8: 1281-1287.
14. Páez-Pereda M, Kovalovsky D, Hopfner U, Theodoropoulou M, Pagotto U, et al. (2001) Retinoic acid prevents experimental Cushing syndrome. J Clin Invest 108: 1123-1131.
15. Castillo V, Giacomini D, Páez-Pereda M, Stalla J, Labeur M, et al. (2006) Retinoic acid as a novel medical therapy for Cushing’s disease in dogs. Endocrinology 147: 4438-4444.
16. Pecori Giraldi F, Ambrogio AG, Andrioli M, Sanguin F, Karamouzis I, et al. (2012) Potential role for retinoic acid in patients with Cushing’s disease. J Clin Endocrinol Metab 97: 3577-3583.
17. Cho JH, Kwon IS, Kim S, Ghil SH, Tsai MJ, et al. (2001) Overexpression of BETA2/NeuroD induces neurite outgrowth in F11 neuroblastoma cells. J Neurochem 77: 103-109.
18. Kim JW, Seghers V, Cho JH, Kang Y, Kim S, et al. (2002) Transactivation of the mouse sulfonylurea receptor I gene by BETA2/NeuroD. Mol Endocrinol 16: 1097-1107.
19. Uruno A, Matsuda K, Noguchi N, Yoshikawa T, Kudo M, et al. (2011) Peroxisome proliferator-activated receptor-γ suppresses CYP11B2 expression and aldosterone production. J Mol Endocrinol 46: 37-49.
20. Leroy P, Nakshatri H, Chambon P (1991) Mouse retinoic acid α2 receptor isoform is transcribed from a promoter that contains a retinoic acid response element. Proc Natl Acad Sci U S A 88: 10138-10142.
21. Lehmann JM, Zhang XK, Pfahl M (1992) RAR γ2 expression is regulated through a retinoic acid response element embedded in Sp1 sites. Mol Cell Biol 12: 2976-2985.
22. Umemiya H, Fukasawa H, Ebisawa M, Eyrolles L, Kawachi E, et al. (1997) Regulation of retinoidal actions by diazepinylbenzoic acids. Retinoid synergists which activate the RXR-RAR heterodimers. J Med Chem 40: 4222-4234.
23. Poulin G, Turgeon B, Drouin J (1997) NeuroD1/beta2 contributes to cell-specific transcription of the proopiomelanocortin gene. Mol Cell Biol 17: 6673-6682.
24. Poulin G, Lebel M, Chamberland M, Paradis FW, Drouin J (2000) Specific protein-protein interaction between basic helix-loop-helix transcription factors and homeoproteins of the Pitx family. Mol Cell Biol 20: 4826-4837.
25. Lamolet B, Pulichino AM, Lamonerie T, Gauthier Y, Brue T, et al. (2001) A pituitary cell-restricted T box factor, Tpit, activates POMC transcription in cooperation with Pitx homeoproteins. Cell 104: 849-859.
26. Giacomini D, Páez-Pereda M, Theodoropoulou M, Labeur M, Refojo D, et al. (2006) Bone morphogenetic protein-4 inhibits corticotroph tumor cells: involvement in the retinoic acid inhibitory action. Endocrinology 147: 247-256.
27. Saito-Hakoda A, Uruno A, Shimizu K, Kudo M, Saito-Ito T, et al. (2012) Retinoid X receptor agonists differentially affect proliferation, apoptosis, and ACTH secretion/POMC gene expression in AtT20 corticotroph cells. Endocr Rev 33: SAT-482 (Abstract).
28. Széles L, Póliska S, Nagy G, Szatmari I, Szanto A, et al. (2010) Research resource: transcriptome profiling of genes regulated by RXR and its permissive and nonpermissive partners in differentiating monocyte-derived dendritic cells. Mol Endocrinol 24: 2218-2231.
29. Aghi MK (2008) Management of recurrent and refractory Cushing disease. Nat Clin Pract Endocrinol Metab 4: 560-568.
30. Heaney AP (2003) Novel pituitary ligands: peroxisome proliferator activating receptor-γ. Pituitary 6: 153-159.
31. Suri D, Weiss RE (2005) Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing’s disease. J Clin Endocrinol Metab 90: 1340-1346.
32. Mullan KR, Leslie H, McCance DR, Sheridan B, Atkinson AB (2006) The PPAR-γ activator rosiglitazone fails to lower plasma ACTH levels in patients with Nelson’s syndrome. Clin Endocrinol (Oxf) 64: 519-522.
33. Pulichino AM, Vallette-Kasic S, Tsai JP, Couture C, Gauthier Y, et al. (2003) Tpit determines alternate fates during pituitary cell differentiation. Genes Dev 17: 738-747.
34. Tateno T, Izumiyama H, Doi M, Yoshimoto T, Shichiri M, et al. (2007) Differential gene expression in ACTH -secreting and non-functioning pituitary tumors. Eur J Endocrinol 157: 717-724.
35. Lamolet B, Poulin G, Chu K, Guillemot F, Tsai MJ, et al. (2004) Tpit-independent function of NeuroD1(BETA2) in pituitary corticotroph differentiation. Mol Endocrinol 18: 995-1003.
36. Oyama K, Sanno N, Teramoto A, Osamura RY (2001) Expression of neuro D1 in human normal pituitaries and pituitary adenomas. Mod Pathol 14: 892-899.
37. Tahara S, Kurotani R, Ishii Y, Sanno N, Teramoto A, et al. (2002) A case of Cushing’s disease caused by pituitary adenoma producing adrenocorticotropic hormone and growth hormone concomitantly: aberrant expression of transcription factors NeuroD1 and Pit-1 as a proposed mechanism. Mod Pathol 15: 1102-1105.